Health Care & Life Sciences » Pharmaceuticals | Spring Bank Pharmaceuticals Inc.

Spring Bank Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
651.00
738.00
946.00
352.00
-
288
Cost of Goods Sold (COGS) incl. D&A
-
-
-
-
158.00
288
Gross Income
-
-
-
-
158.00
288
SG&A Expense
5,694.00
8,502.00
12,454.00
19,638.00
21,095.00
27,861
EBIT
5,071.00
7,806.00
11,596.00
19,404.00
21,253.00
28,149
Unusual Expense
54.00
-
-
1,942.00
6,795.00
4,348
Interest Expense
1,951.00
1,907.00
6.00
-
-
-
Pretax Income
6,956.00
9,712.00
11,564.00
17,366.00
27,679.00
22,854
Consolidated Net Income
6,956.00
9,712.00
11,564.00
17,366.00
27,679.00
22,854
Net Income
6,956.00
9,712.00
11,564.00
17,366.00
27,679.00
22,854
Net Income After Extraordinaries
6,956.00
9,712.00
11,564.00
17,366.00
27,679.00
22,854
Net Income Available to Common
6,956.00
9,712.00
11,564.00
17,366.00
27,679.00
22,854
EPS (Basic)
0.60
0.78
1.60
2.39
2.48
1.88
Basic Shares Outstanding
24,184.50
24,184.50
7,229.10
7,256.70
11,153.30
14,372.20
EPS (Diluted)
0.29
0.40
1.60
2.39
2.48
1.88
Diluted Shares Outstanding
24,184.50
24,184.50
7,229.10
7,256.70
11,153.30
14,619
EBITDA
5,043.00
7,764.00
11,508.00
19,286.00
21,095.00
27,861
Non-Operating Interest Income
12.00
1.00
38.00
96.00
369.00
999

About Spring Bank Pharmaceuticals

View Profile
Address
35 Parkwood Drive
Hopkinton Massachusetts 01748
United States
Employees -
Website http://www.springbankpharm.com
Updated 07/08/2019
Spring Bank Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its pipeline include RIG-I & STING Agonists platforms. The company was founded by Douglas J.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.